31 results
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
and cash equivalents, for (i) ongoing research and development activities; (ii) working capital and general corporate purposes; and (iii) investment in other … Company Limited” on September 10, 2021. It is primarily engaged in the research and development of T-Cell blood analysis.
Virax Biolabs Pte. Limited
6-K
EX-99.2
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
Operating Expenses
Sales and marketing
Research & development
General and administration
Total operating expenses
Operating loss
Other income/(expense … September 30,
Operating expenses:
Sales and marketing
Research and development
General and administration
Total operating expenses
Components of Operating
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
of revenue - excluding depreciation
Operating expenses:
Sales and Marketing
Research & Development
General and Administration
Total operating expenses … of the Company and primarily engaged in the Company's research and development activities.
Virax Biolabs Limited (“HKCo” or formerly known as Shanghai
424B3
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
20 Dec 23
Prospectus supplement
4:03pm
T-Cell Medical Device Company Limited” on September 10, 2021. It is primarily engaged in the research and development of T-Cell blood analysis.
Virax
F-3
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
5 Dec 23
Shelf registration (foreign)
4:06pm
. It is primarily engaged in the research and development of T-Cell blood analysis.
Virax Biolabs Pte. Limited (“SingaporeCo”) — Virax Biolabs Pte. Limited … ” and effected a name change to “Virax Immune T-Cell Medical Device Company Limited” on September 10, 2021. It is primarily engaged in the research and development of T
D
nayymigepjk8vve5dz
17 Oct 23
$2.15 mm in equity / options / securities to be acquired, sold $2.15 mm, 1 investor
4:05pm
6-K
EX-99.1
hrob2 5oqw
1 Sep 23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
7:37am
6-K
EX-99.1
8xtkke4ub5kdfqkuq
14 Jun 23
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
8:00am
424B3
08vg2sk 1lzxdb
31 Mar 23
Prospectus supplement
4:04pm
424B3
6647r8wp
2 Dec 22
Prospectus supplement
4:17pm
F-1
6870eaz3xea2kp
18 Nov 22
Registration statement (foreign)
5:39pm
20-F
aq1vb48s75t77w3 dat0
12 Aug 22
Annual report (foreign)
4:20pm
424B4
kfhqs1yux6jud ph445y
21 Jul 22
Prospectus supplement with pricing info
10:01am
FWP
jqs f7ilsdr32pplqrs
30 Jun 22
Free writing prospectus
9:04pm
FWP
dlplraak t9f
30 Jun 22
Free writing prospectus
1:29pm
F-1/A
j1r gcsrq
24 Jun 22
Registration statement (foreign) (amended)
9:47pm
F-1/A
1xk25mxgi7p
24 Jun 22
Registration statement (foreign) (amended)
8:21am
F-1/A
tkln2v8602rzbrnxw
21 Jun 22
Registration statement (foreign) (amended)
6:26am
F-1/A
qkoaswq4vc
6 Jun 22
Registration statement (foreign) (amended)
6:13pm